Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role

@article{Alexopoulos2017TripleAT,
  title={Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role},
  author={D. Alexopoulos and Panagiotis Vlachakis and John Lekakis},
  journal={Cardiovascular Drugs and Therapy},
  year={2017},
  volume={31},
  pages={319-324}
}
Triple antithrombotic therapy (TAT), consisting of aspirin, a P2Y12 receptor antagonist and oral anticoagulant (OAC) medication has been considered as an ‘unavoidable’ strategy for a 1–12 months for atrial fibrillation (AF) patients post acute coronary syndrome or percutaneous coronary angioplasty with stenting. However, TAT has rather poorly been adopted in real life practice, mainly because of an accompanying increased bleeding potential and lack of definitive results of randomized clinical… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology • 2010
View 4 Excerpts
Highly Influenced

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.

The New England journal of medicine • 2016
View 2 Excerpts
Highly Influenced

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery • 2016
View 2 Excerpts

Similar Papers

Loading similar papers…